PMID- 30799999
OWN - NLM
STAT- MEDLINE
DCOM- 20190611
LR  - 20200225
IS  - 1466-1861 (Electronic)
IS  - 0962-9351 (Print)
IS  - 0962-9351 (Linking)
VI  - 2019
DP  - 2019
TI  - Quetiapine Attenuates the Neuroinflammation and Executive Function Deficit in 
      Streptozotocin-Induced Diabetic Mice.
PG  - 1236082
LID - 10.1155/2019/1236082 [doi]
LID - 1236082
AB  - Diabetic patients are at increased risk for developing memory and cognitive 
      deficit. Prior studies indicate that neuroinflammation might be one important 
      underlying mechanism responsible for this deficit. Quetiapine (QTP) reportedly 
      exerts a significant neuroprotective effect in animal and human studies. Here, we 
      investigated whether QTP could prevent memory deterioration and cognitive 
      impairment in a streptozotocin- (STZ-) induced diabetic mouse model. In this 
      study, we found that STZ significantly compromised the behavioral performance of 
      mice in a puzzle box test, but administering QTP effectively attenuated this 
      behavioral deficit. Moreover, our results showed that QTP could significantly 
      inhibit the activation of astrocytes and microglia in these diabetic mice and 
      reduce the generation and release of two cytokines, tumor necrosis factor-alpha 
      (TNF-alpha) and monocyte chemoattractant protein-1 (MCP-1). Meanwhile, QTP also 
      prevented the protein loss of the synaptic protein synaptophysin (SYP) and myelin 
      basic protein (MBP). Here, our results indicate that QTP could inhibit 
      neuroinflammatory response from glial cells and block the injury of released 
      cytokines to neurons and oligodendrocytes in diabetic mice (DM). These beneficial 
      effects could protect diabetic mice from the memory and cognitive deficit. QTP 
      may be a potential treatment compound to handle the memory and cognitive 
      dysfunction in diabetic patients.
FAU - Wang, Kexin
AU  - Wang K
AD  - Department of General Surgery, Qilu Hospital of Shandong University, Jinan, 
      Shandong, China.
FAU - Song, Feng
AU  - Song F
AUID- ORCID: 0000-0002-2765-195X
AD  - Department of Orthopedics, Qingdao University Affiliated Qingdao Municipal 
      Hospital, Qingdao, Shandong, China.
FAU - Wang, Hongxing
AU  - Wang H
AD  - Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 
      China.
FAU - Wang, Jun-Hui
AU  - Wang JH
AUID- ORCID: 0000-0003-4187-3441
AD  - University of Toronto, Department of Physiology, Toronto, Ontario, Canada.
FAU - Sun, Yu
AU  - Sun Y
AUID- ORCID: 0000-0002-1286-1823
AD  - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, 
      Shandong, China.
LA  - eng
PT  - Journal Article
DEP - 20190117
PL  - United States
TA  - Mediators Inflamm
JT  - Mediators of inflammation
JID - 9209001
RN  - 0 (Ccl2 protein, mouse)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Neuroprotective Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 2S3PL1B6UJ (Quetiapine Fumarate)
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Animals
MH  - Astrocytes/drug effects
MH  - Chemokine CCL2/metabolism
MH  - Cognition Disorders/prevention & control
MH  - Cognitive Dysfunction/prevention & control
MH  - Diabetes Mellitus, Experimental/drug therapy/physiopathology
MH  - Disease Models, Animal
MH  - Executive Function/drug effects
MH  - Male
MH  - Memory/drug effects
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Microglia/drug effects
MH  - Neuroprotective Agents/therapeutic use
MH  - Quetiapine Fumarate/*therapeutic use
MH  - Streptozocin/toxicity
MH  - Tumor Necrosis Factor-alpha/metabolism
PMC - PMC6360057
EDAT- 2019/02/26 06:00
MHDA- 2019/06/14 06:00
PMCR- 2019/01/17
CRDT- 2019/02/26 06:00
PHST- 2018/06/25 00:00 [received]
PHST- 2018/11/17 00:00 [revised]
PHST- 2018/12/17 00:00 [accepted]
PHST- 2019/02/26 06:00 [entrez]
PHST- 2019/02/26 06:00 [pubmed]
PHST- 2019/06/14 06:00 [medline]
PHST- 2019/01/17 00:00 [pmc-release]
AID - 10.1155/2019/1236082 [doi]
PST - epublish
SO  - Mediators Inflamm. 2019 Jan 17;2019:1236082. doi: 10.1155/2019/1236082. 
      eCollection 2019.